Harrow, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Harrow, Inc. (HROW) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $399.00 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-08-11
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $182.00K, a 8.08% decline year-over-year.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $217.00K, a 11.86% increase year-over-year.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $268.00K, a 43.32% increase year-over-year.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $244.00K, a 32.61% increase year-over-year.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $904.00K, a 24.18% increase from fiscal 2023.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $728.00K, a 19.34% increase from fiscal 2022.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $610.00K, a 17.76% increase from fiscal 2021.
- Harrow, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $518.00K, a 25.57% decline from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $399.00K 10-Q · filed 2025-08-11 | $667.00K derived: sum of 3 quarters · filed 2025-08-11 | $911.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | $217.00K 10-Q · filed 2025-05-08 | $485.00K derived: sum of 2 quarters · filed 2025-05-08 | $729.00K derived: sum of 3 quarters · filed 2025-05-08 | $927.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $512.00K derived: sum of 2 quarters · filed 2025-03-27 | $710.00K derived: sum of 3 quarters · filed 2025-08-11 | $904.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $442.00K derived: sum of 2 quarters · filed 2025-08-11 | $636.00K 10-Q · filed 2024-11-14 | $823.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-06-30 | $198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $392.00K 10-Q · filed 2025-08-11 | $579.00K derived: sum of 3 quarters · filed 2025-08-11 | $763.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $194.00K 10-Q · filed 2025-05-08 | $381.00K derived: sum of 2 quarters · filed 2025-05-08 | $565.00K derived: sum of 3 quarters · filed 2025-05-08 | $745.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $371.00K derived: sum of 2 quarters · filed 2025-03-27 | $551.00K derived: sum of 3 quarters · filed 2025-03-27 | $728.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $364.00K derived: sum of 2 quarters · filed 2024-11-14 | $541.00K 10-Q · filed 2024-11-14 | $716.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $180.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $357.00K 10-Q · filed 2024-08-07 | $532.00K derived: sum of 3 quarters · filed 2024-08-07 | $704.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $177.00K 10-Q · filed 2024-05-13 | $352.00K derived: sum of 2 quarters · filed 2024-05-13 | $524.00K derived: sum of 3 quarters · filed 2024-05-13 | $663.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $347.00K derived: sum of 2 quarters · filed 2024-03-19 | $486.00K derived: sum of 3 quarters · filed 2024-03-19 | $610.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $172.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $311.00K derived: sum of 2 quarters · filed 2023-11-13 | $435.00K 10-Q · filed 2023-11-13 | $531.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $139.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $263.00K 10-Q · filed 2023-08-09 | $359.00K derived: sum of 3 quarters · filed 2023-08-09 | $482.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $124.00K 10-Q · filed 2023-05-11 | $220.00K derived: sum of 2 quarters · filed 2023-05-11 | $343.00K derived: sum of 3 quarters · filed 2023-05-11 | $494.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $219.00K derived: sum of 2 quarters · filed 2023-03-23 | $370.00K derived: sum of 3 quarters · filed 2023-03-23 | $518.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $274.00K derived: sum of 2 quarters · filed 2022-11-14 | $422.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $151.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $299.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $148.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $696.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |